

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
30 March 2006 (30.03.2006)

PCT

(10) International Publication Number
WO 2006/032869 A1

(51) International Patent Classification:

C07D 409/04 (2006.01) **A61K 31/551** (2006.01)
C07D 409/14 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:

PCT/GB2005/003621

(22) International Filing Date:

20 September 2005 (20.09.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/611,515 20 September 2004 (20.09.2004) US

(71) Applicants (*for all designated States except US*): **KUDOS PHARMACEUTICALS LIMITED** [GB/GB]; 327 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0WG (GB). **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; Sardinia House, Sardinia Street, London Greater, London WC2A 3NL (GB).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SMITH, Greame, Cameron, Murray** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0WG (GB). **MARTIN, Niall, Morrison, Barr** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0WG (GB). **MENEAR, Keith, Allan** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge,

Cambridgeshire CB4 0WG (GB). **HUMMERSONE, Marc, Geoffrey** [GB/GB]; Kudos Pharmaceuticals Limited, 327 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0WG (GB). **RIGOREAU, Laurent, Jean, Martin** [FR/GB]; Cancer Research Technology Limited, Wolfson Institute for Biomedical Research, University College London, Gower Street, London Greater London WC1E 6BT (GB). **GRIFFIN, Roger, John** [GB/GB]; School of Natural Sciences - Chemistry, Bedson Building, University of Newcastle Upon Tyne, Newcastle Upon Tyne, Tyne and Wear NE1 7RU (GB). **GOLDING, Bernard Thomas** [GB/GB]; School of Natural Sciences - Chemistry, Bedson Building, University of Newcastle Upon Tyne, Newcastle Upon Tyne, Tyne and Wear NE1 7RU (GB). **NEWELL, David, Richard** [GB/GB]; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle Upon Tyne, Tyne and Wear NE46 3EN (GB). **CALVERT, Hilary, Alan** [GB/GB]; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle Upon Tyne, Tyne and Wear NE46 3EN (GB). **CURTIN, Nicola Jane** [GB/GB]; Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle Upon Tyne, Tyne and Wear NE46 3EN (GB). **HARDCASTLE, Ian, Robert** [GB/GB]; School of Natural Sciences - Chemistry, Bedson Building, University of Newcastle Upon Tyne, Newcastle Upon Tyne, Tyne and Wear NE1 7RU (GB). **SARAVANAN, Kappusamy** [IN/GB]; School of Natural Sciences - Chemistry, Bedson Building, University of Newcastle Upon Tyne, Newcastle Upon Tyne, Tyne and Wear NE1 7RU (GB).

[Continued on next page]

(54) Title: DNA-PK INHIBITORS



(I)

(57) **Abstract:** A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R^1 and R^2 are independently selected from hydrogen, an optionally substituted C_{1-7} alkyl group, C_{3-20} heterocyclyl group, or C_{5-20} aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is $-NH-C(=O)-$ or $-O-$; Y is an optionally substituted C_{1-5} alkylene group; X is selected from SR^3 or NR^4R^5 , wherein, R^3 , or R^4 and R^5 are independently selected from hydrogen, optionally substituted C_{1-7} alkyl, C_{5-20} aryl, or C_{3-20} heterocyclyl groups, or R^4 and R^5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is $-O-$, X is additionally selected from $-C(=O)-NR^6R^7$, wherein R^6 and R^7 are independently selected from hydrogen, optionally substituted C_{1-7} alkyl, C_{5-20} aryl, or C_{3-20} heterocyclyl groups, or R^6 and R^7 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and if Q is $-NH-C(=O)-$, $-Y-X$ may additionally be selected from C_{1-7} alkyl.



(74) **Agents:** WATSON, Robert et al.; Mewburn Ellis LLP,
York House, 23 Kingsway, London Greater, London
WC2B 6HP (GB).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.